Lantheus Shareholders Face Scrutiny Over $102.50 Per Share Sale to Curium
Event summary
- Halper Sadeh LLC is investigating Lantheus Holdings' $102.50 per share sale to Curium US Holdings, including potential $12.00 per share in Contingent Value Rights.
- The law firm alleges Lantheus' board may have failed to obtain the best price or conduct a fair process.
- Investigation focuses on potential violations of securities laws and breach of fiduciary duties.
- Contingent Value Rights are tied to commercial milestones through 2030.
The big picture
This investigation highlights growing shareholder activism in healthcare M&A, particularly around diagnostic and radiopharmaceutical companies. The $102.50 per share offer price represents a 25% premium to Lantheus' 30-day average, but the inclusion of Contingent Value Rights suggests uncertainty around future performance. The case could set a precedent for how boards handle similar transactions under regulatory and shareholder pressure.
What we're watching
- Governance Dynamics
- Whether Lantheus' board can justify the sale price and process under shareholder scrutiny.
- Regulatory Headwinds
- How potential securities law violations could impact the deal's timeline or terms.
- Execution Risk
- The pace at which Curium can integrate Lantheus and achieve the commercial milestones tied to Contingent Value Rights.
Related topics